Vermillion (VRML) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vermillion Reports First Quarter 2015 Financial Results and Provides Business Update
May 11, 2015 4:01 PM EDTAUSTIN, Texas, May 11, 2015 /PRNewswire/ --Â Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported financial results for the first quarter ended March 31, 2015 and provided a business update.
Valerie Palmieri, President and CEO of Vermillion, Inc., stated, "The first quarter marked a number of significant accomplishments and we are on track and, in some cases, ahead of our 2015 milestone plan. In addition to our submission of OVA2® to the FDA, we presented strong results from a breakthrough health economics study, gained traction in our efforts to drive... More
